Institute Catalá Oncología -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2020

  1. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

2016

  1. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation

    Bone Marrow Transplantation, Vol. 51, Núm. 1, pp. 79-82

2013

  1. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

    Annals of Hematology, Vol. 92, Núm. 9, pp. 1151-1179

2010

  1. International network of cancer genome projects

    Nature, Vol. 464, Núm. 7291, pp. 993-998

2005

  1. Minor histocompatibility antigen HA-8 mismatch and clinical outcome after hla-identical sibling donor allogeneic stem cell transplantation

    Haematologica, Vol. 90, Núm. 12, pp. 1723-1724

2004

  1. HLA-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease

    Transplantation, Vol. 77, Núm. 7, pp. 1107-1110

2001

  1. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation

    British Journal of Haematology, Vol. 114, Núm. 4, pp. 931-936

1998

  1. Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

    Annals of Oncology, Vol. 9, Núm. 8, pp. 849-855